Trial Profile
A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 25 Feb 2019 Planned End Date changed from 1 Mar 2017 to 1 Dec 2019.
- 25 Feb 2019 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2019.
- 25 Feb 2019 Status changed from not yet recruiting to recruiting.